InsiderTrades.com logo
The #1 Energy Stock to Buy
From Wall Street Watch Dogs   |   Ad
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Get the Name & Ticker Here

RENE Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £55,900
Insider Selling (Last 12 Months): GBX 0

ReNeuron Group Insider Trading History Chart

This chart shows the insider buying and selling history at ReNeuron Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ReNeuron Group Share Price & Price History

Current Price: GBX 10.74
Price Change: ▼ Price Decrease of -0.39 (-3.51%)
As of 02/7/2023 06:54 AM ET

This chart shows the closing price history over time for RENE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
A gold storm is coming…
From Wall Street Watch Dogs   |   Ad
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]

ReNeuron Group Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/23/2023Iain G RossInsiderBuy100,000GBX 10£10,000
9/2/2022Iain G RossInsiderBuy30,000GBX 26£7,800
7/12/2022Barbara StaehelinInsiderBuy127,000GBX 30£38,100
10/20/2021Barbara StaehelinInsiderBuy43,000GBX 115£49,450
See Full Table
A gold storm is coming…
From Wall Street Watch Dogs   |   Ad
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]

SEC Filings (Institutional Ownership Changes) for ReNeuron Group (LON:RENE)

ReNeuron Group logo
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Read More on ReNeuron Group

Today's Range

Now: GBX 10.74
Low: 10.50
High: 11.13

50 Day Range

MA: GBX 11.16
Low: 8.75
High: 23.50

52 Week Range

Now: GBX 10.74
Low: 8.50
High: 44.50

Volume

286,427 shs

Average Volume

628,865 shs

Market Capitalization

£6.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of ReNeuron Group?

ReNeuron Group's top insider investors include:
  1. Barbara Staehelin (Insider)
  2. Iain G Ross (Insider)
Learn More about top insider investors at ReNeuron Group.
Profit From the Commercial Solar Boom?
From Investing Trends   |   Ad
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
See What's Going on With the Solar Industry